Sidi Chen, PhD: The Light at the End of the Tunnel

Years Funded: 2020-2022

Initial Development of a Novel CRISPRa-Based Immune Gene Therapy for PDAC
Sidi Chen, PhD, assistant professor in the Yale University School of Medicine Department of Genetics, Systems Biology Institute and Cancer Center (West Haven, CT) is taking on the challenges of pancreatic cancer with an innovative, versatile and highly scalable strategy he calls MAEGI — Multiplexed Activation of Endogenous Genes as an Immunotherapy.

Read More
Michael T. Lotze, MD: To Each His Own Adaptome

Years Funded: 2020-2022

Tumor Infiltrating Gamma Delta T Cells for Pancreatic Cancer Treatment
An immune response to pancreatic cancer has been elusive. With funding from ACGT, Michael T. Lotze, MD, vice chair of research at the University of Pittsburgh School of Medicine Department of Surgery (Pittsburgh, PA) is pioneering the potential of a less appreciated, less abundant, and less studied class of T cells known as gamma delta T cells to confront pancreatic and other solid tumor cancers.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.